G.J.S. Rustin

Hillingdon Hospitals NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

25h-index3.3kcitations83works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(25), Testicular diseases and treatments(15), Gestational Trophoblastic Disease Studies(13), Medical Imaging Techniques and Applications(6), Endometrial and Cervical Cancer Treatments(6)

Publications83 total

714P Prognostic factors in stage I seminoma: Data from the phase III, randomised TRial of Imaging and Surveillance in Seminoma Testis (TRISST)
Annals of Oncology·2021
2606 PET-CT as a predictor of recurrence after standard dose salvage chemotherapy for relapsed germ cell tumours. Results from the Gem-TIP study
European Journal of Cancer·2015
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
UCL Discovery (University College London)·2013· 102 cited
The role of CA 125 in epithelial ovarian carcinoma.
PubMed·2012· 1 cited
380 Phase I trial of OXi4503: positron emission tomography (PET) analysis shows early effects on tumour perfusion that predict metabolic response
European Journal of Cancer Supplements·2010
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.
Journal of Clinical Oncology·2010· 4 cited
Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
Journal of Clinical Oncology·2010· 26 cited
3BA Randomized MRC OV05/EORTC 55955 trial in recurrent ovarian cancer: early treatment based on increased serum CA125 alone versus delayed treatment based on conventional clinical indicators
European Journal of Cancer Supplements·2009· 1 cited
Salvage chemotherapy with gemcitabine, paclitaxel, ifosphamide, and cisplatin (Gem-TIP) for relapsed germ cell tumours (GCT)
Journal of Clinical Oncology·2009· 1 cited
A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
Journal of Clinical Oncology·2008· 42 cited
A phase I/II trial of radioimmunotherapy with <sup>131</sup>Iodine labelled A5B7 anti-CEA antibody (<sup>131</sup>I-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas
Journal of Clinical Oncology·2008· 4 cited
Phase I evaluation of vascular disrupting agent OXi4503
Journal of Clinical Oncology·2008· 9 cited
5031 POSTER Combination chemotherapy with carboplatin and gemcitabine in patients in platinum-resistant ovarian cancer chemotherapy: a phase II study demonstrating inhibition of DNA cross-link repair by gemcitabine
European Journal of Cancer Supplements·2007· 1 cited
Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma
Journal of Clinical Oncology·2007· 5 cited
Combretastatin A-4 phosphate
Drugs of the Future·2007· 32 cited
18FDG PET in the prediction of relapse in patients with high risk, clinical stage I non-seminomatous germ cell tumours: Preliminary report of MRC Trial TE22
UCL Discovery (University College London)·2007
Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours
2006· 8 cited
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Annals of Oncology·2005· 465 cited
Clinical trials in ovarian carcinoma: study methodology
Annals of Oncology·2005· 29 citedOpen Access
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Annals of Oncology·2005· 9 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

E.S. Newlands(9), Stuart Kaye(7), K. D. Bagshawe(7), E. A. Eisenhauer(5), Ann E. Nelstrop(5), Rhj Begent(5), Ignace Vergote(4), H Lambert(4), ES Newlands(4), K D Bagshawe(4), Andreas du Bois(3), Mark F. Brady(3), Seija Grénman(3), Jean‐Paul Guastalla(3), P. Harper(3), Thomas Högberg(3), Robert F. Ozols(3), Éric Pujade-Lauraine(3), Justine Rochon(3), Satoru Sagae(3)